We also mined the clinical data of glioblastoma cohorts in TCGA, PanCancer Atlas and found that alterations in mTOR, STAT3, and CDK6 constituted 5% of the genetic alteration occurring in GBM patients (Figure 2C). This evidence concerns the gene CDK6 and glioblastoma.